Lupin Ltd gained for a third straight session today. The stock is quoting at Rs 2205.2, up 2.25% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 1.01% on the day, quoting at 24425.65. The Sensex is at 80274.05, up 1.1%. Lupin Ltd has gained around 0.64% in last one month. Meanwhile, Nifty Pharma index of which Lupin Ltd is a constituent, has gained around 2.07% in last one month and is currently quoting at 22574.55, up 1% on the day. The volume in the stock stood at 9.05 lakh shares today, compared to the daily average of 9.34 lakh shares in last one month. The benchmark October futures contract for the stock is quoting at Rs 2205.05, up 2.17% on the day. Lupin Ltd is up 93.38% in last one year as compared to a 27.61% jump in NIFTY and a 54.31% jump in the Nifty Pharma index.The PE of the stock is 35.89 based on TTM earnings ending June 24.Powered by Capital Market - Live

Lupin has allotted 51,609 equity shares under ESOP on 23 October 2024. The issued and paid-up capital of the Company has been increased to Rs 91,23,89,842 consisting of 45,61,94,921 equity shares of Rs 2/- each.Powered by Capital Market - Live

Lupin will hold a meeting of the Board of Directors of the Company on 7 November 2024.Powered by Capital Market - Live

Being the first generic to be approved and launched, the company is entitled to 180-day competitive generic therapy (CGT) exclusivity. Prednisolone Acetate Ophthalmic Suspension is a generic equivalent of Pred Forte Ophthalmic Suspension of AbbVie, Inc. It is indicated for the treatment of steroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe. Pred Forte had estimated annual sales of $198 million in the U.S., IQVIA MAT August 2024. Vinita Gupta, CEO, Lupin, said: 'The launch of Prednisolone Acetate Ophthalmic Suspension is a milestone and is aligned with our commitment to enhancing access to innovative, affordable and quality healthcare solutions. This will strengthen our ophthalmic portfolio and will benefit patients seeking effective treatment for steroid-responsive inflammation.' Mumbai-based Lupin is an innovation-led transnational pharmaceutical company. It develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S, India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions. The company's consolidated net profit jumped 76.01% to Rs 801.31 crore during the quarter as compared with Rs 452.26 crore posted in Q1 FY24. Revenue from operations increased 16.28% YoY to Rs 5,514.34 crore during the quarter. Powered by Capital Market - Live

Lupin announced the launch of the first generic version of Pred Forte' (Prednisolone Acetate) Ophthalmic Suspension USP, 1% in the United States. Being the first generic to be approved and launched, the company is entitled to 180-day competitive generic therapy (CGT) exclusivity. Prednisolone Acetate Ophthalmic Suspension USP, 1% is a generic equivalent of Pred Forte' Ophthalmic Suspension, 1% of AbbVie, Inc. and is indicated for the treatment of steroid responsive inflammation of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe. Pred Forte' had estimated annual sales of USD 198 million in the U.S. (IQVIA MAT August 2024). Powered by Capital Market - Live

The inspection was carried out from 25 September 2024 to 04 October 2024, and concluded with five observations. The company is addressing the observations comprehensively and will respond to the U.S. FDA within the stipulated timeframe. Mumbai-based Lupin is an innovation-led transnational pharmaceutical company. It develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S, India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions. The company's consolidated net profit jumped 76.01% to Rs 801.31 crore during the quarter as compared with Rs 452.26 crore posted in Q1 FY24. Revenue from operations increased 16.28% YoY to Rs 5,514.34 crore during the quarter. The scrip had advanced 0.65% to end at Rs 2197.60 on the BSE on Friday. Powered by Capital Market - Live

The inspection concluded with 3 observations on both the API and Finished Product sides. The pharmaceutical major is addressing these observations comprehensively and will respond to the USFDA within the stipulated timeframe. Mumbai-based Lupin is an innovation-led transnational pharmaceutical company. It develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S, India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions. The company's consolidated net profit jumped 76.01% to Rs 801.31 crore during the quarter as compared with Rs 452.26 crore posted in Q1 FY24. Revenue from operations increased 16.28% YoY to Rs 5,514.34 crore during the quarter. Shares of Lupin gained 1.56% to end at Rs 2,221.50 on Friday, 27 September 2024. Powered by Capital Market - Live

Lupin informed that the U.S. FDA inspected Lupin's Pithampur Unit-1 API and finished product manufacturing facility from 16 September to 27 September 2024. The inspection closed with three observations each on the API and Finished Product side.Powered by Capital Market - Live

Lupin has allotted 5,893 equity shares under ESOP on 20 September 2024. Post allotment, the issued and paid-up capital of the Company has been increased to Rs 91,22,86,624 consisting of 45,61,43,312 equity shares of Rs 2/- each.Powered by Capital Market - Live

Vonoprazan is a novel potassium-competitive acid blocker (P-CAB). Unlike traditional acid suppressants like PPIs, Vonoprazan offers unique attributes like complete proton pump inhibition with the first dose, longer duration of action resulting in effective control of nocturnal acid breakthrough and meal-independent dosing. In India, Vonoprazan is approved by the Drug Controller General of India (DCGI) for treating reflux esophagitis, gastric ulcers, duodenal ulcers, and as part of Helicobacter pylori eradication treatment. The said drug will be marketed under the brand name Lupin's Lupivon and will be available in two strengths 10 mg and 20 mg. Under the terms of this agreement, Takeda has granted Lupin non-exclusive patent licensing rights to commercialize Vonoprazan in India. Rajeev Sibal, president India region formulations, Lupin,We are very pleased to commercialize Vonoprazan, a novel treatment option for Acid Peptic Disorders. This is a further step in strengthening our gastroenterology portfolio and is in line with our commitment to introduce innovative medicines to address unmet needs of our patients.' Mumbai-based Lupin is an innovation-led transnational pharmaceutical company. It develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S, India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions. The company's consolidated net profit jumped 76.01% to Rs 801.31 crore during the quarter as compared with Rs 452.26 crore posted in Q1 FY24. Revenue from operations increased 16.28% YoY to Rs 5,514.34 crore during the quarter. The scrip declined 2.32% to Rs 2,217.85Powered by Capital Market - Live